BACKGROUND AND OBJECTIVES: To improve the likelihood of achieving a margin-free resection, neoadjuvant induction chemotherapy with GTX (gemcitabine, docetaxel, and capecitabine) followed by 5-FU-IMRT was administered to patients with borderline resectable pancreatic cancer. The utility of computed tomography (CT), endoscopic ultrasound (EUS), positron emission tomography (PET), and CA 19-9 during diagnostic workup and assessment of response was also examined. METHODS: Seventeen patients with borderline resectable pancreatic cancer received a median of three cycles of neoadjuvant GTX induction chemotherapy followed by 5-FU-IMRT with dose painting. CA 19-9, CT mass size, and PET SUV were examined before and after neoadjuvant treatment. RESULTS: Diagnostic EUS and CT scans displayed similar mean mass sizes and extent of vascular involvement. Eight of the 17 patients achieved an R0 resection. Median CA 19-9 levels, CT mass size, and PET SUV all significantly decreased after neoadjuvant therapy. The median progression-free survival and overall survival were 10.48 and 15.64 months, respectively. Six patients are still alive. CONCLUSIONS: Neoadjuvant GTX induction chemotherapy followed by 5-FU-IMRT shows promise in improving the likelihood of resectability with negative margins in borderline resectable pancreatic cancer. CT and EUS play complimentary roles during diagnostic workup. CT scans, CA 19-9, and PET scans are useful in judging response to neoadjuvant therapy.
BACKGROUND AND OBJECTIVES: To improve the likelihood of achieving a margin-free resection, neoadjuvant induction chemotherapy with GTX (gemcitabine, docetaxel, and capecitabine) followed by 5-FU-IMRT was administered to patients with borderline resectable pancreatic cancer. The utility of computed tomography (CT), endoscopic ultrasound (EUS), positron emission tomography (PET), and CA 19-9 during diagnostic workup and assessment of response was also examined. METHODS: Seventeen patients with borderline resectable pancreatic cancer received a median of three cycles of neoadjuvant GTX induction chemotherapy followed by 5-FU-IMRT with dose painting. CA 19-9, CT mass size, and PET SUV were examined before and after neoadjuvant treatment. RESULTS: Diagnostic EUS and CT scans displayed similar mean mass sizes and extent of vascular involvement. Eight of the 17 patients achieved an R0 resection. Median CA 19-9 levels, CT mass size, and PET SUV all significantly decreased after neoadjuvant therapy. The median progression-free survival and overall survival were 10.48 and 15.64 months, respectively. Six patients are still alive. CONCLUSIONS: Neoadjuvant GTX induction chemotherapy followed by 5-FU-IMRT shows promise in improving the likelihood of resectability with negative margins in borderline resectable pancreatic cancer. CT and EUS play complimentary roles during diagnostic workup. CT scans, CA 19-9, and PET scans are useful in judging response to neoadjuvant therapy.
Authors: J P Neoptolemos; D D Stocken; J A Dunn; J Almond; H G Beger; P Pederzoli; C Bassi; C Dervenis; L Fernandez-Cruz; F Lacaine; J Buckels; M Deakin; F A Adab; R Sutton; C Imrie; I Ihse; T Tihanyi; A Olah; S Pedrazzoli; D Spooner; D J Kerr; H Friess; M W Büchler Journal: Ann Surg Date: 2001-12 Impact factor: 12.969
Authors: Jerome Landry; Paul J Catalano; Charles Staley; Wayne Harris; John Hoffman; Mark Talamonti; Natalie Xu; Harry Cooper; Al B Benson Journal: J Surg Oncol Date: 2010-06-01 Impact factor: 3.454
Authors: Christopher H Crane; James L Abbruzzese; Douglas B Evans; Robert A Wolff; Mathew T Ballo; Marc Delclos; Luka Milas; K Mason; C Charnsangavej; P W T Pisters; J E Lee; R Lenzi; J N Vauthey; A B S Wong; T Phan; Q Nguyen; N A Janjan Journal: Int J Radiat Oncol Biol Phys Date: 2002-04-01 Impact factor: 7.038
Authors: J F Pingpank; J P Hoffman; E A Ross; H S Cooper; N J Meropol; G Freedman; W H Pinover; T E LeVoyer; A R Sasson; B L Eisenberg Journal: J Gastrointest Surg Date: 2001 Mar-Apr Impact factor: 3.452
Authors: Howard Safran; Thomas Dipetrillo; David Iannitti; Daniel Quirk; Paul Akerman; Dennis Cruff; William Cioffi; Samir Shah; Nadia Ramdin; Tyvin Rich Journal: Int J Radiat Oncol Biol Phys Date: 2002-09-01 Impact factor: 7.038
Authors: Shalini Moningi; Avani S Dholakia; Siva P Raman; Amanda Blackford; John L Cameron; Dung T Le; Ana M C De Jesus-Acosta; Amy Hacker-Prietz; Lauren M Rosati; Ryan K Assadi; Shirl Dipasquale; Timothy M Pawlik; Lei Zheng; Matthew J Weiss; Daniel A Laheru; Christopher L Wolfgang; Joseph M Herman Journal: Ann Surg Oncol Date: 2015-01-07 Impact factor: 5.344
Authors: Samhita Chakraborty; Monica M Morris; Todd W Bauer; Reid B Adams; Edward B Stelow; Gina Petroni; Hanna K Sanoff Journal: Gastrointest Cancer Res Date: 2014-01
Authors: Shaunagh McDermott; Sarah P Thayer; Carlos Fernandez-Del Castillo; Mari Mino-Kenudson; Ralph Weissleder; Mukesh G Harisinghani Journal: Transl Oncol Date: 2013-12-01 Impact factor: 4.243